Kymera Therapeutics Inc (KYMR)
24.82 -1.54 (-5.84%) 13:03 ET [NASDAQ]
24.80 x 100 24.88 x 1
Realtime by (Cboe BZX)
24.80 x 100 24.88 x 1
Realtime 24.61 -1.75 (-6.64%) 09:30 ET
for Thu, Apr 3rd, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Cash Flows From Operating Activities | |||||
Net Income | -223,858 | -146,962 | -154,808 | -100,217 | -45,593 |
Depreciation Amortization | -6,610 | -1,664 | 3,866 | 8,204 | 3,334 |
Accounts receivable | 15,000 | -15,000 | N/A | 577 | -577 |
Accounts payable and accrued liabilities | -307 | 2,038 | 253 | 54 | 990 |
Other Working Capital | -23,970 | 2,682 | -37,623 | -61,923 | 124,867 |
Other Operating Activity | 45,244 | 56,080 | 35,227 | 24,359 | 5,109 |
Operating Cash Flow | $-194,501 | $-102,826 | $-153,085 | $-128,946 | $88,130 |
Cash Flows From Investing Activities | |||||
PPE Investments | -12,838 | -34,480 | -2,836 | -1,597 | -9,096 |
Purchase Of Investment | -901,226 | -189,151 | -445,972 | -456,404 | -529,382 |
Sale Of Investment | 509,987 | 363,517 | 469,327 | 358,166 | 115,890 |
Investing Cash Flow | $-404,077 | $139,886 | $20,519 | $-99,835 | $-422,588 |
Cash Flows From Financing Activities | |||||
Debt Repayment | -1,576 | -76 | -1,130 | -849 | -554 |
Common Stock Issued | 610,427 | 4,268 | 154,129 | 251,526 | 196,835 |
Other Financing Activity | 0 | 0 | 0 | -397 | 92,981 |
Financing Cash Flow | $608,851 | $4,192 | $152,999 | $250,280 | $289,262 |
Beginning Cash Position | 115,777 | 74,525 | 54,092 | 32,593 | 77,789 |
End Cash Position | 126,050 | 115,777 | 74,525 | 54,092 | 32,593 |
Net Cash Flow | $10,273 | $41,252 | $20,433 | $21,499 | $-45,196 |
Free Cash Flow | |||||
Operating Cash Flow | -194,501 | -102,826 | -153,085 | -128,946 | 88,130 |
Capital Expenditure | -12,838 | -34,480 | -2,836 | -1,597 | -9,096 |
Free Cash Flow | -207,339 | -137,306 | -155,921 | -130,543 | 79,034 |